NUVB Earnings

NUVB reported its FY2025Q4 earnings on 2026-03-02, showcasing a revenue of against an estimate of 27.43M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.11 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NUVB's FY2025Q4 earnings announcement on 2026-03-02, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NUVB's stock price tends to shift by an average of -3.54% in the 10 days leading up to earnings and 0.56% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NUVB's annual revenue to reach 32.58M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NUVB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NUVB's stock price typically moves by -3.54% in the 10 days before its earnings and 0.56% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.10 and revenue of 32.58M.

The earnings call highlighted strong financial metrics with $549 million in cash and a significant increase in new patient starts for IBTROZI. However, management's reluctance to provide specific sales guidance and lack of details on the IDH1 program raise concerns. The advanced European partnership talks and expected $25 million milestone are positive, but the absence of clear guidance tempers optimism. The Q&A revealed a cautious analyst sentiment due to these uncertainties, leading to a neutral outlook for the stock price.